Inhalation Sciences signs IRS order worth 1.17 million SEK with large generic pharma company
Inhalation Sciences has signed a new contract worth 1.17 million SEK (107,600 Euros) for an Inhalation Research Service (IRS) project aiming to establish differences in the dissolution profiles between a generic inhaled therapy and its reference drug – a key component of bioequivalence.
Dissolution data are a crucial component of bioequivalence, a key requirement that a generic drug needs to comply to for regulatory approval. Bioequivalence is particularly challenging to define for inhaled drugs - a fast-growing market segment that is forecast to grow from 17.5 BUSD (2021) to 38.45 BUSD by 2030 (1).
ISAB’s high-precision in vitro dissolution and absorption module DissolvIt® is a leader in this field. It can generate dissolution and absorption data that are close to ‘IVIVC’ (In Vitro in Vivo Correlated) and so can closely predict the pharmacokinetic processes in humans. DissolvIt® is in high demand and ISAB has several IVIVC research projects ongoing.
ISAB CEO Manoush Masarrat: “Our IRS research services meet the growing need for research tools specifically targeted and tailored to the physiological processes of the lung. We welcome this further confirmation of the expertise of our team, and the excellent capabilities of DissolvIt®. We look forward to beginning work on this exciting project.”
- BioSpace august 2022 ‘Inhalation And Nasal Spray Generic Drugs Market Size To Surpass US$ 38.45 BN By 2030’
READ MORE
Explore DissolvIt’s capabilities here.
Read ISAB’s publications on DissolvIt® here.
Explore Inhalation Research Services here
